• Researcher Profile

    Philip W. Kantoff, MD

    Philip W. Kantoff, MD

    Top Doctor

    Chief, Division of Solid Tumor Oncology
    Director, Lank Center for Genitourinary Oncology
    Chair, Executive Committee for Clinical Research
    Institute Physician

    Professor of Medicine, Harvard Medical School


    Genitourinary Oncology

    Office phone: 617-632-1914
    Fax: 617-632-2165
    Email: philip_kantoff@dfci.harvard.edu

    Preferred contact method: office phone

    View Physician Profile

    Research Department

    Medical Oncology/Solid Tumor Oncology


    Prostate cancer, Testicular cancer

    Area of Research

    Genitourinary Cancers: Genetics, Epidemiology, and Clinical Trials

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1230
    Boston, MA 02215


    Dr. Kantoff graduated from Brown University Medical School in 1979. After completing his internship and residency in internal medicine at New York University Hospital and Bellevue Hospital, he spent four years at the National Institutes of Health conducting research in gene therapy. He joined DFCI in 1987 and became director of the Lank Center for Genitourinary Oncology in 1988. Dr. Kantoff is chief clinical research officer and chief of the Division of Solid Tumor Oncology at Dana-Farber. He is the leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program, and director of the prostate cancer Specialized Program of Research Excellence (SPORE). He is Professor of Medicine at Harvard Medical School.


    Genitourinary Cancers: Genetics, Epidemiology, and Clinical Trials

    Our research team focuses on the molecular basis of genitourinary cancers and improved treatments for patients with prostate cancer, kidney cancer, bladder cancer, and testicular cancer. Laboratory research involves understanding the genetics of prostate cancer, while clinical research focuses on trials of novel therapeutics for genitourinary cancers.

    In our laboratory, we have investigated germline and somatic genetic markers of prostate cancer phenotype, mechanisms of resistance to hormone therapy and the role of microRNAs in prostate cancer. Our clinical trials have focused on: - introducing chemotherapy or novel therapeutics to patients with high-risk localized prostate cancer - testing novel therapeutics in men with rising levels of prostate-specific antigen (PSA) following local therapy with agents such as rosiglitazone and celecoxib - testing novel theraputics in men with advanced prostate disease - treating renal cell carcinoma with antiVEGF-based therapies - Our work has led to the FDA approval of drugs for prostate cancer including chemotherapies mitoxatrone and cabazitaxel, to vaccines including Provenge. We have also played vital roles in the development of abiraterone and XL 184.

    Select Publications

    • Eglitis MA, Kantoff PW, Gilboa E, Anderson WF.  Gene expression in mice after high efficiency retroviral-mediated gene transfer.  Science 1985;230:1395-8.
    • Kantoff PW, Kohn DB, Mitsuya H, Armentano D, Sieberg M, Zwiebel JA, Eglitis MA, McLachlin JR, Wiginton DA, Hutton JJ, Horowitz SD, Gilboa E, Blaese RM, Anderson WF.  Correction of adenosine deaminase deficiency in human T and B cells using retroviral-mediated gene transfer.  Proc Natl Acad Sci USA 1986;83:6563-7.
    • Kantoff PW, Gillio A, McLachlin JR, Bordignon C, Eglitis MA, Kernan N, Moen R, Kohn DB, Karson E, Karlsson S, Zwiebel JA, Gilboa E, Blaese RM, Nienhuis A, O’Reilly R, Anderson WF.  Expression of human adenosine deaminase in non-human primates after retroviral mediated gene transfer.  J Exp Med 1987;166:219-34.
    • Kantoff PW, Flake AW, Eglitis MA, Harrison MR, Gilboa E, Zanjani ED, Anderson WF.  In utero gene transfer and expression: a sheep transplantation model.  Blood 1989;73:1066-73.
    • Giovannucci E, Stampfer M, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens C, Kantoff PW.  The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.  Proc Natl Acad Sci 1997;94:3320-3323.
    • Brufsky A, Fontaine P, Berlane K, Reiker P, Jiroutek M, Kaplan I, Kaufman D, Kantoff PW.  Finasteride and flutamide as potency sparing androgen ablative therapy for prostate cancer.  Urology 1997;49(6):913-920.
    • Ghossein R, Rosai J, Scher H, Seiden M, Krithivas K, Chang G, Berlane K, Kantoff PW.  Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 1997;50(1):100-105.
    • Talcott JA, Rieker P, Propert K, Clark J, Wishnow KI, Loughlin KR, Cunnion M, Richie J, Kantoff PW.  Patient reported impotence and incontinence after nerve-sparing radical prostatectomy.  JNCI 1997;89(15):1117-1123.
    • Talcott JA, Rieker P, Clark J, Propert K, Kalish L, Weeks J, Beard C, Wishnow KI, Kaplan I, Loughlin KR, Cram R, Richie J, Kantoff PW.  Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study.  J Clin Onc 1998;16:275-283.
    • Kavoussi LR, Nelson JB, Chen RN, Bishoff JT, Donehower RC, Baltimore MD, Oh WK, Kantoff PW.  Laparoscopic retroperitoneal lymph node dissection (RPLND) for clinical stage 1 nonseminomatous germ cell testicular tumors (NSGCT).  Urology 1999 Dec;54(6):1064-7.
    • Kantoff PW, Yurgalevitch SM, Krithivas K, Brown M, Mohr BA, McKinlay JB, Longcope C.  Evidence that the CAG repeat in the androgen receptor gene modulates serum androgen levels.  J. Endoc 1999;162(1):137-42.
    • Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N.  Hydrocortisone (H) with or without mitoxantrone (M) in men with hormone refractory prostate cancer (HRPC).  The results of CALGB 9182.  J Clin Onc 1999;17(8):2506-13.
    • Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman D, Oh W, Demetri G, Figg W, Zhou X, Eng C, Spiegelman B, Kantoff PW.  Effects of ligand activation of PPAR ?in human prostate cancer.  Proc Natl Acad Sci 2000;97:10,990-95.
    • D’Amico A, Schultz D, Loffredo M, Dugal R, Hurwitz M, Beard C, Kaplan I, Renshaw A, Kantoff PW.  Biochemical outcome following radiation therapy with or without androgen suppression therapy with clinically localized prostate cancer.  JAMA 2000 Sep. 13;284(10):1280-3.
    • Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW.  Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer.  Urology 2001;57(3).
    • Kantoff PW, Halabi S, Farmer DA, Hayes DF, Vogelzang NA, Small EJ. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate specific antigen in men with androgen independent prostate cancer. J Clin Oncol 2001 Jun 15:19(12):2238-45.
    • George DJ, Halabi S, Shepard TF, Volgelzang N, Hayes DF, Small EJ, Kantoff PW. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.  Clin Cancer Res 2001 Jul;7(7):1932-6.
    • Halabi S, Hayes D, Vogelzang N, Small E, Kantoff PW.  The prognostic significance of reverse transcriptase polymerase chain reaction (RT-PCR) for prostate specific antigen (PSA) in prostate cancer patients with one prior hormonal therapy: a nested study within CALGB 9583.  J Clin Oncol Feb 2003;21(3):490-495.
    • Oh, WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW.  Finasteride and flutamide therapy in patients with advanced prostate cancer:  response to subsequent castration and long-term follow-up.  Urology 2003;62:99-104.
    • D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW.  6-month androgen suppression plus radiation therapy vs radiation therapy with clinically localized prostate cancer.  JAMA 2004 Aug 18;292(7):821-7.
    • George D, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 (IL-6) levels in patients with metastatic hormone-refractory prostate cancer (HRCaP): Results from CALGB 9480.  Clin Cancer Res 2005 Mar 1;11(5):1815-20.
    • Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma chromogranin A levels in hormone-refractory prostate cancer patients treated on Cancer and Leukemia Group B (CALGB) 9480.  Urology 2005 Aug;66(2):386-91
    • Li H, Kantoff PW Giovannucci E, Leitzmann M, Gaziano JM, Stampfer MJ, Ma J.  Manganese superoxide dismutase (MnSOD) polymorphism, prediagnostic plasma antioxidants and prostate cancer risk.  Cancer Res 2005 Mar 15;65(6):2498-504.
    • Ross RW, Manola J, Hennessey K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.  Clin Cancer Res 2005 Jul 15;11(14):5195-8
    • Smith MR, Manola J, Kaufman DS, Oh WK, Bubley JG, Kantoff PW.  Celecoxib versus placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy.  J Clin Oncol. 2006 Jun 20;24(18):2723-8.
    • Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda MA, Sellers WR, Richie JP, Kantoff PW, Weeks J.  Development of an integrated prostate cancer research information system: Prostate CRIS. Clin Genitourin Cancer. 2006 Jun;5(1):61-6. #-equal contribution
    • D’Amico AV, Goldhaber SZ; Chen MH, Loffredo M, RN, Renshaw AA, Loffredo B; PW Kantoff,  Hormonal Therapy for Prostate Cancer and the Time Course to Cardiovascular Death.  J. Clin Onc 2007 Jun 10;25(17):2420-5.
    • D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen Suppression and Radiation vs Radiation for Prostate Cancer: A Randomized Trial and Analysis of the Prognostic Significance of Comorbidity.  JAMA. 2008 Jan 23;299(3):289-95.
    • Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME,. Regan MM, Kantoff PW*, Freedman M* Inherited variation in the androgen pathway is associated with the efficacy of androgen deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20;26(6):842-7. *-contributed equally.
    • D’Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW.  Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy.  J Clin Oncol. 2008 Jun 20;26(18):2979-83
    • Chan JM*, Oh WK*, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. *Contributed equally.  Plasma selenium, manganese superoxide dismutase (SOD2), and intermediate or high risk prostate cancer. J Clin Oncol. 2009 Jun 15. [Epub ahead of print]
    • Sun T, Wang Q, Balk S, Brown M, Lee GS and Kantoff PW. The role of microRNA-221 and -222 in Androgen-independent Prostate Cancer Cell lines.  Cancer Res. 2009 Apr 15;69(8):3356-63. Epub 2009 Apr 7.
    • Wang Q, Li W, Zhang Y, Yuan X, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Chinnaiyan A, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS and Brown M. Reprogrammed androgen receptor function in androgen independent prostate cancer. Cell 2009 Jul 23;138(2):245-56.
    • Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, and Godfrey WR Overall survival (OS) analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2010 Jan 25. [Epub ahead of print]
    • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, and Schellhammer PF for the IMPACT Study Investigators. Sipuleucel-T, Immunotherapy for Castration Resistant Prostate Cancer. N.Eng. J.Med 2010. 363:5: 1-12.
    • Hayes JH,  Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl  JE. McMahon PM. Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis. JAMA. 2010 Dec 1;304(21):2373-80.
    • Berger MF, Lawrence MS, Demichelis F, Cibulskis K, Sivachenko A, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter S, Drier Y, Ambrogio L, Fenne T, Parkin M, Gordon S, Voet D, Ramos A, Pugh T, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Kitabayashi N, MacDonald TY, Kantoff PW, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA. Characterization of complex chromosomal aberrations in primary prostate cancer genomes. Nature 2011 Feb 10;470(7333):214-20.
    • Yang M, Xie W, Mostaghel E, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M,. Oh WK, Lee GSM, Kantoff PW. SLCO2B1 and SLCO1B3 are pharmacogenomic determinants of resistance to androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 May 23. [Epub ahead of print]
    • Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GSM* Kantoff PW* The Impact of Common Genetic Variations in Genes of the Sex Hormone Metabolic Pathways on Steroid Hormone Levels and Prostate Cancer Aggressiveness.  Cancer Prevention Research Cancer Prev Res (Phila). 2011 Sep 7. [Epub ahead of print]
    • Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI,. Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin M, Rosenberg JE, and Kantoff PW. A Double Blind Randomized Trial of Docetaxel + Vandetanib vs. Docetaxel + Placebo, in Platinum-Pretreated Metastatic Urothelial Cancer.  J Clin Oncol. 2011 Dec 19. [Epub ahead of print]
    • Sun T,Yang M,Chen S, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GSM, Kantoff PW. The Altered Expression of MiR-221/-222 and MiR-23b/-27b is Associated with the Development of Human Castration Resistant Prostate Cancer. Prostate. 2011 Nov 29. doi: 10.1002/pros.22456. [Epub ahead of print]
    • D’Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, Kantoff PW,*  Denham JW* co-last author.  Surrogate Endpoint for Prostate Cancer Specific Mortality Following Radiation and Androgen Suppression Therapy for Men with Localized or Locally Advanced Prostate Cancer: Analysis of Randomized Trials.  Lancet Oncol. 2012 Feb;13 (2):189-95. Epub 2011 Nov 21.
    • Ross RW, Galsky M.D, Scher HI, Magidson J, Wassmann K, Lee GWM, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK, A Whole Blood RNA Transcript-Based Prognostic Model in Men with Castration-Resistant Prostate Cancer.  Lancet Oncol. 2012 Oct 8. pii: S1470-2045(12)70263-2. doi: 10.1016/S1470-2045(12)70263-2. [Epub ahead of print]
    • Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, Macdonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.Nat Genet. 2012 May 20. doi: 10.1038/ng.2279. [Epub ahead of print] PMID:22610119
    • Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson B, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack E, Lis R, Kantoff PW, Loda M, Sartor OA, Shin E, Tewari AK, Hahn WC, Freedman ML Genetic and Functional Analyses Implicate NUDT11, HNF1B, and SLC22A3 in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11252-7. doi: 10.1073/pnas.1200853109. Epub 2012 Jun 22
    • Xu K, Wu ZJ, Groner AC, He HH, Cai C, Liu T, Lis RT, Wu X, Stack EC, Loda M, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Kantoff PW, Balk SP, Liu* XS, Brown M* EZH2 Oncogenic Activity in Castration Resistant Prostate Cancer is Polycomb-Independent.  Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604
    • Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline PSA is associated with a greater overall survival benefit from sipuleucel-T in the IMPACT trial. Urology. 2013 Apr 9. doi:pii: S0090-4295(13)00225-2. 10.1016/j.urology.2013.01.061. [Epub ahead of print]
    • Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, Macdonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, Nickerson E, Auclair D, Tewari A, Beltran H, Onofrio RC, Boysen G, Guiducci C, Barbieri CE, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Ramos AH, Winckler W, Cipicchio M, Ardlie K, Kantoff PW, Berger MF, Gabriel SB, Golub TR, Meyerson M, Lander ES, Elemento O, Getz G, Demichelis F, Rubin MA, Garraway LA. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25;153(3):666-77.
    • Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW. Clinical Predictors of Survival in Men with Castration-resistant Prostate Cancer: Evidence that Gleason 6 Cancer Can Evolve to Lethal Disease.  Cancer. 2013 May 29. doi: 10.1002/cncr.28102. [Epub ahead of print]
    • Hayes JH, Ollendorf DA, Pearson SD, Barry MJ,  Kantoff PW, Lee PA. McMahon PM. Observation vs. initial treatment for men with localized low-risk prostate cancer A Cost Effectiveness Analysis.  Ann Intern Med. 2013 Jun 18;158(12):853-60. doi: 10.7326/0003-4819-158-12-201306180-00002.
    • Sun T, Wang X, He HH, Sweeney CJ, Liu S, Brown M, Balk S, Lee GSM, Kantoff PW. MED1, HECTD2 and RAB1A are targets of miR-221/222 that promote the development of androgen independence in prostate cancer cells. Oncogene. 2013 Jun 17. doi: 10.1038/onc.2013.230. [Epub ahead of print]
    • Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini D, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 Mar 13. [Epub ahead of print]
    • Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis J, Zhang C, Shalek AK, Satija R, Trombetta JT, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GSM, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC. Whole exome sequencing of CTCs as a window into metastatic prostate cancer. Nat Biotech Nat Biotechnol. 2014 Apr 20. doi: 10.1038/nbt.2892. [Epub ahead of print]
    • Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, Sun T, Sweeney CL, Lee GSM, Liu XS, Brown M, Kantoff PW. Enhancer RNAs Participate in Androgen Receptor-Driven Looping that Selectively Enhances Gene Activation. Proc Natl Acad Sci U S A. 2014 Apr 28. [Epub ahead of print]
    • Van Allen EM, Wagle N, Stojanov P, Perrin D, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich D, Kryukov G, Carter S, McKenna A, Sivachenko A, Keizun A, Voet D, Lawrence M, Lichtenstein L, Gentry J, Huang FW, Farlow D, Barbie D, Gandhi L, Lander ES, Gray S, Joffe S, Janne P, Garber J, Macconail L, Lindeman N, Rollins B, Kantoff PW, Fisher S, Gabriel S, Getz G, Garraway LA. Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision oncology.  Nat Med. 2014 Jun;20(6):682-8. doi: 10.1038/nm.3559. Epub 2014 May 18.
    • Recklitis CJ, Zhou ES, Zwemer E, Hu JC, Kantoff PW. Prevalence and correlates of suicidal ideation in prostate cancer survivors. Cancer (in press)
    • Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda ML, Davis JW, Loda M, True LD Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran NP, Peng W, Kheoh T, Molina A, Kantoff PW. Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study.  J. Clin. Onc (in press)


    • Elfiky, Aymen, MD
    • Rosenberg, Jonathan, MD
    • Freedman, Matthew, MD
    • Choueiri, Toni, MD
    • Hayes, Julia, MD
    • Pomerantz, Mark, MD


    • Sun, Tong, PhD
    • Hsieh, Chen-Lin, PhD
View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer

Give Now